Search

Incyte Corp

Fermé

SecteurSoins de santé

124.38 -2.51

Résumé

Variation du prix de l'action

24h

Actuel

Min

125.67

Max

128.13

Chiffres clés

By Trading Economics

Revenu

282M

586M

Ventes

401M

1.7B

P/E

Moyenne du Secteur

16.282

57.366

BPA

2.8

Marge bénéficiaire

34.982

Employés

2,844

EBITDA

384M

752M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+2.39% upside

Dividendes

By Acuity

Prochains Résultats

27 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.2B

26B

Ouverture précédente

126.89

Clôture précédente

124.38

Sentiment de l'Actualité

By Acuity

16%

84%

24 / 340 Classement par Healthcare

Incyte Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 août 2026, 20:07 UTC

News

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

26 août 2026, 19:36 UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

25 août 2026, 23:21 UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

24 août 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

21 août 2026, 19:46 UTC

News

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

20 août 2026, 23:41 UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

19 août 2026, 23:01 UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

17 août 2026, 20:06 UTC

News

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

14 août 2026, 19:36 UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

13 août 2026, 23:26 UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

10 août 2026, 19:36 UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

6 août 2026, 19:44 UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

5 août 2026, 19:56 UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

4 août 2026, 19:46 UTC

News

Mizuho raised its price target on Incyte Corp to $137, maintaining an Outperform rating. Analyst Josh Brown's comments on CNBC contributed to positive sentiment today.

3 août 2026, 23:56 UTC

Incyte Corp shares are higher in after-market hours, recovering from five consecutive daily declines. Broader market sentiment remains positive amid declining oil prices.

31 juil. 2026, 22:21 UTC

Incyte Corp's shares are higher in after-market trading, driven by a rise in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

30 juil. 2026, 23:56 UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of declines since Thursday's close amid broader market pressures.

29 juil. 2026, 22:51 UTC

Event

Incyte Corp shares are higher after the European Commission approved Opzelura® for moderate atopic dermatitis treatment. Market conditions are also advancing in after-market trading.

28 juil. 2026, 23:02 UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline influenced by concerns over technology stocks and geopolitical tensions.

27 juil. 2026, 23:02 UTC

Incyte Corp shares are lower in after-market hours, following a decline earlier in the session amid broader market sentiment influenced by falling crude oil prices.

24 juil. 2026, 21:01 UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment was affected by a sharp Nasdaq decline.

22 juil. 2026, 20:04 UTC

Incyte Corp's shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average and near the upper end of its one-month range.

21 juil. 2026, 16:36 UTC

Social Media
News

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to gains in Incyte shares during Tuesday's session.

20 juil. 2026, 21:56 UTC

Incyte Corp shares are lower in after-market hours following a volatile session, despite trading above the 20-day moving average and near a one-month high.

17 juil. 2026, 23:16 UTC

Incyte Corp shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the movement.

16 juil. 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours amid a broader market decline, influenced by rising interest rates and geopolitical tensions.

15 juil. 2026, 19:16 UTC

News

Incyte Corp remains elevated above its 20-day moving average, recently surpassing Weyerhaeuser to become the 400th largest company in the S&P 500.

13 juil. 2026, 16:21 UTC

News
Event

Incyte Corp shares are lower amid concerns over revenue guidance despite positive Phase 1/2 data for latarcibart presented at ISTH 2026 Congress.

10 juil. 2026, 20:06 UTC

Incyte Corp's shares are lower today, influenced by declines in the Biotechnology sub-sector. The stock peaked early before steadily declining throughout the session.

9 juil. 2026, 23:56 UTC

Incyte Corp shares are lower in after-market hours amid broader market caution linked to renewed military tensions between the U.S. and Iran.

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

2.39% hausse

Prévisions sur 12 Mois

Moyen 130.79 USD  2.39%

Haut 155 USD

Bas 104 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

21 ratings

11

Achat

10

Maintien

0

Vente

Sentiment

By Acuity

24 / 340Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat